The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.

Vasilios PetrakisPetros RafailidisGrigorios TrypsanisDimitrios PapazoglouPeriklis Panagopoulos

Published in: Viruses (2023)

Oral treatment with nirmatrelvir/ritonavir in high-risk non-hospitalized patients was safe and effective in preventing the severe clinical progress of COVID-19 pneumonia. Early administration of antiviral agents in vulnerable outpatients combined with a full vaccination scheme is significant in order to avoid hospitalization and severe clinical outcomes.

Keyphrases

coronavirus disease
sars cov
early onset
antiretroviral therapy
electronic health record
big data
intensive care unit
smoking cessation
respiratory syndrome coronavirus
deep learning